New analysis seeks to find mutations that predict response to Amgen's Vectibix in colorectal cancer
This article was originally published in Scrip
In a new exploratory, retrospective biomarker analysis of a pivotal trial of Vectibix (panitumumab), Amgen has sought to identify which mutations beyond those in the KRAS proto-oncogene may predict resistance or response to the EGFR targeted drug when it is used to treat metastatic colorectal cancer (mCRC).
You may also be interested in...
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.